Clonal evolution in high-risk MDS and secondary AML treated with venetoclax and azacitidine

被引：0
|
作者：
Koch, R. [1 ]
Ganster, C. [1 ]
Dierks, S. [1 ]
Shirneshan, K. [1 ]
Rittscher, K. [1 ]
Nothnick, G. [1 ]
Becker, S. [1 ]
Shumilov, E. [1 ]
Haase, D. [1 ]
机构：
[1] Univ Med Gottingen, Klin Hamatol & Med Onkol, Gottingen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P724
引用
收藏
页码：199 / 199
页数：1
相关论文
共 50 条
  • [1] Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine
    Pomares, Helena
    Arnan, Montserrat
    Sanchez-Ortega, Isabel
    Sureda, Anna
    Duarte, Rafael F.
    [J]. BLOOD, 2015, 126 (23)
  • [2] INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH HIGH-RISK MDS AND AML TREATED WITH AZACITIDINE
    Pomares Marin, H.
    Arnan Sangerman, M.
    Sanchez-Ortega Sanchez, I.
    Duarte Palomino, R. D.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S145 - S146
  • [3] Venetoclax Plus Azacitidine Versus Azacitidine Alone As Post-Transplant Maintenance Treatment in High-Risk AML and MDS
    Cao, Yigeng
    Guo, Wenwen
    Zhai, Weihua
    Wei, Jialin
    Ma, Qiaoling
    Yang, Donglin
    Pang, AiMing
    Han, Mingzhe
    Jiang, Erlie
    [J]. BLOOD, 2023, 142
  • [4] Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML
    S Ettou
    E Audureau
    C Humbrecht
    B Benet
    H Jammes
    T Clozel
    V Bardet
    C Lacombe
    F Dreyfus
    P Mayeux
    E Solary
    M Fontenay
    [J]. Leukemia, 2012, 26 : 2297 - 2299
  • [5] Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML
    Ettou, S.
    Audureau, E.
    Humbrecht, C.
    Benet, B.
    Jammes, H.
    Clozel, T.
    Bardet, V.
    Lacombe, C.
    Dreyfus, F.
    Mayeux, P.
    Solary, E.
    Fontenay, M.
    [J]. LEUKEMIA, 2012, 26 (10) : 2297 - 2299
  • [6] Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML
    Garcia, Jacqueline S.
    Kim, Haesook T.
    Murdock, H. Moses
    Ansuinelli, Michela
    Brock, Jennifer
    Cutler, Corey S.
    Gooptu, Mahasweta
    Ho, Vincent T.
    Koreth, John
    Nikiforow, Sarah
    Romee, Rizwan
    Shapiro, Roman
    Deangelo, Daniel J.
    Stone, Richard M.
    Bat-Erdene, Denbaa
    Ryan, Jeremy
    Contreras, Manuel E.
    Fell, Geoffrey
    Letai, Anthony
    Ritz, Jerome
    Lindsley, R. Coleman
    Soiffer, Robert J.
    Antin, Joseph H.
    [J]. BLOOD ADVANCES, 2024, 8 (04) : 978 - 990
  • [7] SALVAGE VENETOCLAX COMBINATION THERAPY IN PATIENTS WITH AML TRANSFORMATION AFTER AZACITIDINE THERAPY FAILURE FOR HIGH-RISK MDS - SINGLE-CENTER EXPERIENCE
    Minarik, L.
    Stopka, T.
    Zemanova, Z.
    Sotakova, S.
    Jonasova, A.
    [J]. LEUKEMIA RESEARCH, 2023, 128
  • [8] Azacitidine As Post-Allograft Maintenance Helps Reduce Relapse Risk in High-Risk MDS and AML
    El Cheikh, Jean
    Massoud, Radwan
    Fares, Elie
    Kreidieh, Nabila
    Mahfouz, Rami
    Kharfan-Dabaja, Mohamed A.
    Bazarbachi, Ali
    [J]. BLOOD, 2016, 128 (22)
  • [9] Fast response and tumor lysis syndrome in patients treated with 5-azacitidine and venetoclax for secondary AML originating from MDS/MPN
    Hecht, A.
    Jann, J. -C.
    Hofmann, W. -K.
    Nolte, F.
    Nowak, D.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 41 - 41
  • [10] Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
    Garcia, Jacqueline S.
    Kim, Haesook T.
    Murdock, H. Moses
    Cutler, Corey S.
    Brock, Jennifer
    Gooptu, Mahasweta
    Ho, Vincent T.
    Koreth, John
    Nikiforow, Sarah
    Romee, Rizwan
    Shapiro, Roman
    Loschi, Fiona
    Ryan, Jeremy
    Fell, Geoffrey
    Karp, Hannah Q.
    Lucas, Fabienne
    Kim, Annette S.
    Potter, Danielle
    Mashaka, Thelma
    Stone, Richard M.
    DeAngelo, Daniel J.
    Letai, Anthony
    Lindsley, R. Coleman
    Soiffer, Robert J.
    Antin, Joseph H.
    [J]. BLOOD ADVANCES, 2021, 5 (24) : 5536 - 5545
12345